Literature DB >> 33093298

Distal Tibial Guided Growth for Anterolateral Bowing of the Tibia: Fracture May Be Prevented.

Jennifer C Laine1,2, Susan A Novotny1,2, Elizabeth W Weber1, Andrew G Georgiadis1,2, Mark T Dahl1,2.   

Abstract

BACKGROUND: Congenital pseudarthrosis of the tibia is a rare and challenging pediatric condition. The pre-fracture state, called congenital tibial dysplasia or anterolateral bowing of the tibia, presents a high fracture risk due to underlying bowing and dysplasia. After fracture, there is a substantial risk of nonunion. Any union achieved may be complicated by refracture, deformity, leg-length discrepancy, stiffness, pain, and dysfunction. We present the results of using distal tibial growth modulation to improve tibial alignment and to decrease fracture risk in this condition. To our knowledge, this is the first report of isolated distal tibial growth modulation as the primary surgical treatment for this condition.
METHODS: This is a retrospective study of 10 patients with congenital tibial dysplasia who presented prior to pseudarthrosis and underwent distal tibial growth modulation as a primary treatment. The medical records and radiographs were reviewed for age at the times of diagnosis and treatment, fracture, secondary procedures, complications, residual deformity, cystic changes, and leg-length discrepancy.
RESULTS: Ten patients had a mean follow-up (and standard deviation) of 5.1 ± 1.9 years. No patient sustained a tibial fracture, and no patient developed a tibial pseudarthrosis after guided growth was initiated. The mean age at the initiation of growth modulation was 2.6 ± 1.3 years. Six patients required a plate exchange. The mean residual tibial diaphyseal angular deformity at the most recent follow-up was 4.3° ± 3.2° of varus and 8.4° ± 5.8° in the sagittal plane. Only 1 patient had a clinically important leg-length discrepancy, with the affected leg being longer.
CONCLUSIONS: In this series of 10 patients with congenital tibial dysplasia, distal tibial growth modulation delayed or possibly prevented fracture, decreased tibial malalignment, improved radiographic appearance of bone quality, and preserved leg length. No patient developed tibial fracture or pseudarthrosis after the initiation of guided growth treatment. Although early results are promising, follow-up to maturity is required to define the exact role of this simple outpatient procedure in congenital tibial dysplasia. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2020        PMID: 33093298     DOI: 10.2106/JBJS.20.00657

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

1.  Congenital segmental tibial dysplasia and late onset pseudarthrosis of the tibia.

Authors:  Mahmoud Abdel-Monem El-Rosasy; Mostafa Elsebai Hammad; Abdullah Ahmed Nada
Journal:  J Orthop       Date:  2022-05-06

2.  [Epiphysiodesis and hemiepiphysiodesis : Physeal arrest and guided growth for the lower extremity].

Authors:  Madeleine Willegger; Maryse Bouchard; Reinhard Windhager; Alexander Kolb; Catharina Chiari
Journal:  Orthopade       Date:  2022-03-31       Impact factor: 1.004

3.  Osthole enhances the bone mass of senile osteoporosis and stimulates the expression of osteoprotegerin by activating β-catenin signaling.

Authors:  Zhen-Xiong Jin; Xin-Yuan Liao; Wei-Wei Da; Yong-Jian Zhao; Xiao-Feng Li; De-Zhi Tang
Journal:  Stem Cell Res Ther       Date:  2021-02-27       Impact factor: 6.832

4.  Design of a New "U"-shaped Staple and Its Clinical Application in Postoperative Ankle Valgus of Congenital Pseudarthrosis of the Tibia in Children.

Authors:  Xiongke Hu; Anping Li; Kun Liu; Jiangyan Wu; Haibo Mei
Journal:  Orthop Surg       Date:  2022-07-20       Impact factor: 2.279

5.  Cross-Union Surgery for Congenital Pseudarthrosis of the Tibia.

Authors:  Claire E Shannon; Aaron J Huser; Dror Paley
Journal:  Children (Basel)       Date:  2021-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.